Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy of an antiplatelet agent and a statin is used to reduce the risk of cardiovascular events in patients with or at high risk for atherosclerotic cardiovascular disease. Antiplatelet agents, such as aspirin or P2Y12 inhibitors (e.g., clopidogrel), work by inhibiting platelet aggregation, thereby reducing the formation of blood clots. Statins (e.g., atorvastatin, simvastatin, rosuvastatin) inhibit HMG-CoA reductase in the liver to lower cholesterol synthesis, stabilize atherosclerotic plaques, and reduce vascular inflammation. The combination targets both thrombosis prevention and lipid lowering for synergistic protection against heart attack and stroke[3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on antiplatelet + statin.